The prevalence of TP53 mutations is higher among the hormone receptor-positive and HER2-positive subtypes in our cohort compared to non-Asian premenopausal cancers in TCGA, along with elevated frequencies of TET2 and CDK12 mutations among hormone receptor-positive patients. Here, TP53 is linked to cancer.